Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01882647 · ClinicalTrials.gov registry record · Phase 3
A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305)
A Phase 3 study of Plaque Psoriasis, sponsored by Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 222
- Enrollment target
- 11
- Study locations
NCT01882647: Completed Phase 3 study of Plaque Psoriasis, sponsored by Therapeutics.
NCT01882647 is a Phase 3 study of Plaque Psoriasis that has completed, run by Therapeutics. The registered enrollment target is 222 participants, below the 411-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (46% lower). The trial reports 11 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01882647, a Phase 3 study of Plaque Psoriasis, has completed, sponsored by Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 222 participants
- Enrollment target
- 11
- Study locations
Study Summary
This Phase 3 study has been designed to determine and compare the efficacy and safety of 000-0551 Lotion and Vehicle Lotion applied twice daily for two weeks in subjects with plaque psoriasis.
Primary Outcome
The IGA score is a static evaluation of the overall or "average" degree of severity of a subject's disease, taking into account all of the subject's psoriatic lesions. "Treatment success" is defined as a score of 0 or 1 representing "cleared" or "almost cleared" at Day 15 with at least a two grade decrease in severity score relative to Baseline. IGA is measured on a 5-point scale, ranging from 0 (clear) to 4 (severe/very severe).
Conditions Studied
Interventions
- DRUG 000-0551 Lotion
- DRUG Vehicle Lotion
Study Locations (11)
Florida
- MOORE Clinical Research, Inc. - Brandon
- Florida Academic Dermatology Center - Miami
- Park Avenue Dermatology, PA - Orange Park
New Mexico
- Academic Dermatology Associates - Albuquerque
- Academic Dermatology Associates - Albuquerque
Texas
- Arlington Research Center, Inc. - Arlington
- DermResearch, Inc. - Austin
Alabama
- Total Skin and Beauty Dermatology Center, PC - Birmingham
Indiana
- The Indiana Clinical Trials Center, PC - Plainfield
Michigan
- Hamzavi Dermatology - Fort Gratiot
New Jersey
- The Psoriasis Treatment Center of Central New Jersey - East Windsor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 222 participants |
| Start Date | 2013-06 |
| Est. Completion | 2014-03 |
| Phase | Phase 3 |
What the finished NCT01882647 record still lists
NCT01882647 is an interventional study that assigns participants to a tested intervention. The registered 222 participants enrollment target is mid-sized for trials with a published cap, below the 411-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (46% lower).
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which 000-0551 Lotion is the first listed.
NCT01882647 lists 11 locations in 7 states (Florida, New Mexico, Texas).
Frequently Asked Questions
What is clinical trial NCT01882647 about?
NCT01882647 is a clinical study titled "A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305)". This Phase 3 study has been designed to determine and compare the efficacy and safety of 000-0551 Lotion and Vehicle Lotion applied twice daily for two weeks in subjects with plaque psoriasis.
What is the current status of trial NCT01882647?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 222 participants. The study started on 2013-06. Estimated completion is 2014-03.
What conditions does trial NCT01882647 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT01882647?
The interventions under investigation include: 000-0551 Lotion (DRUG), Vehicle Lotion (DRUG).
Who is sponsoring clinical trial NCT01882647?
This trial is sponsored by Therapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01882647 being conducted?
This trial has 11 study locations across Alabama, Florida, Indiana, Michigan, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01882647's enrollment target sits among peer trials
222 19th of 45 higher than 27 of 45 other Plaque Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Plaque Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
RECRUITING · Phase 3
-
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
ACTIVE NOT RECRUITING · Phase 3
-
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04939610 · 222 participants · Phase 1
A Study of 177Lu-FAP-2286 in Advanced Solid Tumors
- NCT05424783 · 222 participants
MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)
- NCT05568264 · 222 participants · NA
Effects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit
- NCT05605574 · 222 participants · NA
Longitudinal Early Advance Care Planning Discussions and Documentation (LEADD) Program: An Exploratory Study in Adolescents and Young Adults (AYAs) Receiving Hematopoietic Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia